You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科-B(06622.HK)公佈中期業績:上半年總收益飆升至4980萬元
格隆匯 08-29 18:33

格隆匯8月29日丨兆科眼科-B(06622.HK)發佈公吿,截至2024年6月30日止六個月,報吿期內錄得收益增長,展現出公司商業化進展積累的強勁勢頭:於本年度上半年,公司的總收益增加至約人民幣4980萬元,而2023年首六個月則約為人民幣1130萬元。其中,人民幣1560萬元來自銷售公司眼科藥物,包括治療青光眼的藥物貝美素噻嗎洛爾滴眼液(晶貝瑩®)及治療角膜潰瘍的藥物睿保特,以及堡得視®眼罩系列(一種治療輕度乾眼症,另一種治療假性近視)。公司已根據日期為2020年10月2日的產品許可協議就阿達帕林╱鹽酸克林黴素複方凝膠收取里程碑付款,以及就BRIMOCHOLPF的獨家分銷權取得收入,因而錄得許可收入人民幣3410萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account